{"id":2289,"date":"2017-09-07T19:06:20","date_gmt":"2017-09-07T13:36:20","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2289"},"modified":"2021-07-24T12:56:50","modified_gmt":"2021-07-24T07:26:50","slug":"the-business-cocktail-34","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-34","title":{"rendered":"CAR-T Phase I trials; ContraVir Announces; Merck acquired; Excision BioTherapeutics bags $10M"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f5b2db509b4\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f5b2db509b4\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-34\/#Two_ongoing_CAR-T_Phase_I_trials_of_Cellectis_drug_candidate_has_been_put_on_hold_by_FDA_after_a_patients_death\" >Two ongoing CAR-T Phase I trials of Cellectis drug candidate has been put on hold by FDA after a patient\u2019s death<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-34\/#ContraVir_Pharmaceuticals_Announces_Clinical_Trial_Application_Acceptance_in_the_United_Kingdom_by_the_MHRA\" >ContraVir Pharmaceuticals Announces Clinical Trial Application&nbsp;Acceptance in the United Kingdom by the MHRA<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-34\/#Merck_recently_acquired_German_biotech_company_Rigontec_to_fuel_its_I-O_portfolio\" >Merck recently acquired German biotech company Rigontec to fuel its I-O portfolio<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-34\/#Excision_BioTherapeutics_successfully_bags_a_Seed_Funding_of_USD_10_million_led_by_ARTIS_Ventures_to_test_whether_CRISPR_can_cure_HIV\" >Excision BioTherapeutics successfully bags a Seed Funding of USD 10 million led by ARTIS Ventures to test whether CRISPR can cure HIV<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Two_ongoing_CAR-T_Phase_I_trials_of_Cellectis_drug_candidate_has_been_put_on_hold_by_FDA_after_a_patients_death\"><\/span><strong>Two ongoing CAR-T Phase I trials of Cellectis drug candidate has been put on hold by FDA after a patient\u2019s death<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>FDA has put two CAR-T trials on hold&nbsp;following a patient\u2019s death, less than a week after the first ever CAR-T was approved by the US regulatory agency. &nbsp;The patient (78) was suffering from relapsed blastic plasmacytoid dendritic cell neoplasm (BPDCN). The patient died 9 days after the administration of&nbsp;Cellectis\u2019 UCART123&nbsp;after experiencing severe cytokine release syndrome (CRS) and a grade 4 capillary leak syndrome (CLS), complications that are commonly associated with CAR-T therapies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"ContraVir_Pharmaceuticals_Announces_Clinical_Trial_Application_Acceptance_in_the_United_Kingdom_by_the_MHRA\"><\/span><strong>ContraVir Pharmaceuticals Announces Clinical Trial Application&nbsp;Acceptance in the United Kingdom by the MHRA<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>ContraVir Pharmaceuticals is focused on the development and commercialization of targeted antiviral therapies. It has recently announced that the Clinical Trial Application (CTA) for the formulation optimization clinical program for Tenofovir Exalidex has been approved in the United Kingdom by the MHRA.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Merck_recently_acquired_German_biotech_company_Rigontec_to_fuel_its_I-O_portfolio\"><\/span><strong>Merck recently acquired German biotech company Rigontec to fuel its I-O portfolio<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Pharmaceutical industry giant Merck is spending 115 million euros ($137 million) upfront cash payment and additional contingent payments of up to 349 million euros in future to buyout &nbsp;Rigontec. The Germany-based company accessing the retinoic acid-inducible gene I (RIG-I) pathway, part of the innate immune system. The&nbsp;Company is developing a&nbsp;new immuno-oncology approach for cancer treatment with its leading drug candidate RGT100.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Excision_BioTherapeutics_successfully_bags_a_Seed_Funding_of_USD_10_million_led_by_ARTIS_Ventures_to_test_whether_CRISPR_can_cure_HIV\"><\/span><strong>Excision BioTherapeutics successfully bags a Seed Funding of USD 10 million led by ARTIS Ventures to test whether CRISPR can cure HIV<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Excision BioTherapeutics has recently announced that it has successfully raised USD 10 million in the seed funding round led by ARTIS Ventures. With this financial support,&nbsp;the company can move towards the human clinical trials with its HIV-1 targeted CRISPR platform. In addition Excision BioTherapeutics is expanding its horizon by using this approach towards other viruses by targeting their genetic element.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Two ongoing CAR-T Phase I trials of Cellectis drug candidate has been put on hold by FDA after a patient\u2019s death FDA has put two CAR-T trials on hold&nbsp;following a patient\u2019s death, less than a week after the first ever CAR-T was approved by the US regulatory agency. &nbsp;The patient (78) was suffering from relapsed [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2290,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1016,776,1009,810,1007,1011,647,1010,1015,297,395,1014,1013,1012,1008,593],"industry":[17225],"therapeutic_areas":[17235,17228,17278],"class_list":["post-2289","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-artis-ventures","tag-business-cocktail","tag-capillary-leak-syndrome","tag-car-t","tag-cellectis","tag-contravir-pharmaceuticals","tag-crispr","tag-cytokine-release-syndrome","tag-excision-biotherapeutics","tag-hiv","tag-merck","tag-rgt100","tag-rigontec","tag-tenofovir-exalidex","tag-ucart123","tag-us-food-and-drug-administration-fda","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-oncology","therapeutic_areas-other-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>CAR-T Phase I trials; ContraVir Announces; Merck acquired<\/title>\n<meta name=\"description\" content=\"FDA has put two CAR-T trials on hold following a patient\u2019s death, less than a week after the first ever CAR-T was approved by the US regulatory agency....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-34\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CAR-T Phase I trials; ContraVir Announces; Merck acquired\" \/>\n<meta property=\"og:description\" content=\"FDA has put two CAR-T trials on hold following a patient\u2019s death, less than a week after the first ever CAR-T was approved by the US regulatory agency....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-34\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-09-07T13:36:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021353\/pharma-licensing.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"620\" \/>\n\t<meta property=\"og:image:height\" content=\"414\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CAR-T Phase I trials; ContraVir Announces; Merck acquired","description":"FDA has put two CAR-T trials on hold following a patient\u2019s death, less than a week after the first ever CAR-T was approved by the US regulatory agency....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-34","og_locale":"en_US","og_type":"article","og_title":"CAR-T Phase I trials; ContraVir Announces; Merck acquired","og_description":"FDA has put two CAR-T trials on hold following a patient\u2019s death, less than a week after the first ever CAR-T was approved by the US regulatory agency....","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-34","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-09-07T13:36:20+00:00","article_modified_time":"2021-07-24T07:26:50+00:00","og_image":[{"width":620,"height":414,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021353\/pharma-licensing.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-34","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-34","name":"CAR-T Phase I trials; ContraVir Announces; Merck acquired","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-34#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-34#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021353\/pharma-licensing.jpg","datePublished":"2017-09-07T13:36:20+00:00","dateModified":"2021-07-24T07:26:50+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"FDA has put two CAR-T trials on hold following a patient\u2019s death, less than a week after the first ever CAR-T was approved by the US regulatory agency....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-34"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-34#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021353\/pharma-licensing.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021353\/pharma-licensing.jpg","width":620,"height":414,"caption":"Entasis"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021353\/pharma-licensing-300x200.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ARTIS Ventures<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Business Cocktail<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">capillary leak syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CAR-T<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cellectis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ContraVir Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CRISPR<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">cytokine release syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Excision BioTherapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">HIV<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Merck<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">RGT100<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Rigontec<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Tenofovir Exalidex<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">UCART123<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">US Food and Drug Administration (FDA)<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">ARTIS Ventures<\/span>","<span class=\"advgb-post-tax-term\">Business Cocktail<\/span>","<span class=\"advgb-post-tax-term\">capillary leak syndrome<\/span>","<span class=\"advgb-post-tax-term\">CAR-T<\/span>","<span class=\"advgb-post-tax-term\">Cellectis<\/span>","<span class=\"advgb-post-tax-term\">ContraVir Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">CRISPR<\/span>","<span class=\"advgb-post-tax-term\">cytokine release syndrome<\/span>","<span class=\"advgb-post-tax-term\">Excision BioTherapeutics<\/span>","<span class=\"advgb-post-tax-term\">HIV<\/span>","<span class=\"advgb-post-tax-term\">Merck<\/span>","<span class=\"advgb-post-tax-term\">RGT100<\/span>","<span class=\"advgb-post-tax-term\">Rigontec<\/span>","<span class=\"advgb-post-tax-term\">Tenofovir Exalidex<\/span>","<span class=\"advgb-post-tax-term\">UCART123<\/span>","<span class=\"advgb-post-tax-term\">US Food and Drug Administration (FDA)<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Sep 7, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Sep 7, 2017 7:06 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2289","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2289"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2289\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2290"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2289"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2289"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2289"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2289"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2289"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}